Apellis Pharmaceuticals Shares Are Trading Higher After the European Medicines Agency Resets Pegcetacoplan Review for Geographic Atrophy to Day 180 of Initial Assessment.
Apellis Pharmaceuticals Shares Are Trading Higher After the European Medicines Agency Resets Pegcetacoplan Review for Geographic Atrophy to Day 180 of Initial Assessment.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.